AMG 410 for KRAS-Altered Advanced or Metastatic Solid Tumors
This study is testing a new medicine called AMG 410, by itself or with other approved medicines like Pembrolizumab and Panitumumab. It's for people with advanced or metastatic (spread) solid tumors that have a specific change in the KRAS gene. Researchers want to see how safe AMG 410 is, what side effects it might cause, and if it can help shrink tumors. They are looking for the highest dose that is safe and manageable. You would need to have a KRAS gene alteration to join this study. The study will track side effects for up to three years. The current status of this study is unclear.
- Study design
- This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It plans to enroll up to 434 participants.
- What's involved
- You would take AMG 410 as an oral tablet, and potentially receive Pembrolizumab or Panitumumab through an IV (intravenous) infusion. Treatment could continue for up to three years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will track side effects for up to approximately three years after you start treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
At a glance
Conditions
Where it's being run
39 sites across 31 statesStudy leadership
- MD · STUDY_DIRECTOR · Amgen
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants with Dose Limiting Toxicities (DLTs)Up to 28 days
- Number of Participants with Treatment Emergent Adverse Events (TEAEs)Up to approximately 3 years
Clinically significant changes in safety assessments (vital signs, electrocardiograms \[ECGs\], and clinical laboratory tests) are to be reported as adverse events.
- Number of Participants with Serious Adverse Events (SAEs)Up to approximately 3 years
Clinically significant changes in safety assessments (vital signs, ECGs, and clinical laboratory tests) are to be reported as adverse events.